Sravani Gundarlapalli

Researcher

UAMS

Also affiliated: Winthrop Rockefeller Foundation (2021–2022)

Faculty Researcher

5 h-index 23 pubs 70 cited

Research Areas

Biomedical Subjects

Links

Research Group

OverviewAI-generated summary

Sravani Gundarlapalli's research focuses on hematologic malignancies, particularly multiple myeloma, and the outcomes of various treatment modalities. Gundarlapalli has investigated the efficacy of salvage autologous stem cell transplantation in patients with relapsed or refractory multiple myeloma, including those refractory to daratumumab. Further research has explored the feasibility of outpatient stem cell transplantation and identified risk factors for hospital admission. Gundarlapalli has also examined the role of tandem autologous stem cell transplantation in patients with persistent minimal residual disease after initial transplantation and the prognostic significance of such persistent disease. Additionally, Gundarlapalli has contributed to understanding the clinical efficacy of sequencing CD38-targeting monoclonal antibodies in relapsed refractory multiple myeloma and evaluated the corneal toxicity associated with belantamab mafodotin.

Metrics

h-index: 5
Publications: 23
Citations: 70

Selected Publications

In vivo CAR T-cell engineering in B-cell malignancies: A systematic review of emerging clinical and translational evidence. (2026)

Journal of Clinical Oncology DOI OpenAlex
Social vulnerability index as an independent poor prognostic factor in patients with chronic hematological malignancies in Arkansas. (2026)

Journal of Clinical Oncology DOI OpenAlex
Real-World Survival Outcomes of CAR-T and Bispecific T-cell Engagers in Patients with relapsed/refractory DLBCL (2026)

Transplantation and Cellular Therapy DOI OpenAlex
Parameters Influencing Count Recovery Post Autologous Stem Cell Transplantation in Patients with Multiple Myeloma (2022)

Blood DOI OpenAlex
Immunogenicity of Covid-19 Vaccine Among Multiple Myeloma Patients Post Autologous Stem Cell Transplant (2022)

Blood DOI OpenAlex
MM-531 Case Control Study of Outcomes of Autologous Stem Cell Transplantation in Jehovah's Witness Multiple Myeloma Patients (2022)

Clinical Lymphoma Myeloma & Leukemia DOI OpenAlex
Poster: MM-531 Case Control Study of Outcomes of Autologous Stem Cell Transplantation in Jehovah's Witness Multiple Myeloma Patients (2022)

Clinical Lymphoma Myeloma & Leukemia DOI OpenAlex
Corneal toxicity with belantamab mafodotin: Multi‐institutional <scp>real‐life</scp> experience (2022)

American Journal of Hematology 16 citations DOI OpenAlex
Updates in the Management of Multiple Myeloma from the American Society of Hematology Meeting 2021 (2022)

touchREVIEWS in Oncology & Haematology 1 citation DOI OpenAlex
Clinical efficacy of sequencing CD38 targeting monoclonal antibodies in relapsed refractory multiple myeloma: A multi‐institutional experience (2022)

American Journal of Hematology 6 citations DOI OpenAlex
Feasibility of Outpatient Stem Cell Transplantation in Multiple Myeloma and Risk Factors Predictive of Hospital Admission (2022)

Journal of Clinical Medicine 13 citations DOI OpenAlex
Tandem autologous stem cell transplantation in patients with persistent bone marrow minimal residual disease after first transplantation in multiple myeloma (2022)

American Journal of Hematology 6 citations DOI OpenAlex
Eight-Color Flow Cytometry Phenotypic Markers and Disease Progression in Monoclonal Gammopathy of Unknown Significance (2021)

Blood 1 citation DOI OpenAlex
Hematological and infectious complications with CD38 antigen targeting monoclonal antibody-based therapies in multiple myeloma: A meta-analysis of randomized control trials (2021)

Leukemia Research 2 citations DOI OpenAlex
Salvage Autologous Stem Cell Transplantation in Daratumumab-Refractory Multiple Myeloma (2021)

Cancers 14 citations DOI OpenAlex